Clinical data
Routes of
By mouth
Drug class NMDA receptor modulator

AGN-241751 is an orally active small-molecule NMDA receptor modulator which is under development for the treatment of major depressive disorder (MDD).[1][2] It was originated by Naurex and was acquired by Allergan from Aptinyx in May 2018.[1][2] Allergan (previously Naurex) is also developing the NMDA receptor modulators rapastinel (GLYX-13; intravenous) and apimostinel (NRX-1074, AGN-241660; oral) for the treatment of MDD.[3][4][5] Like apimostinel, AGN-241751 is intended as an oral follow-up compound to rapastinel.[2][6] As of May 2018, the drug is in phase I clinical trials.[1][2]

See also


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.